@prefix this: . @prefix sub: . @prefix np: . @prefix dct: . @prefix pav: . @prefix rdf: . @prefix xsd: . @prefix rdfs: . @prefix biolink: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { a biolink:DiseaseOrPhenotypicFeature; rdfs:label "OCD" . a biolink:ChemicalEntity; rdfs:label "Fluoxetine" . a biolink:DiseaseOrPhenotypicFeature; rdfs:label "Obsessive Compulsive Disorder" . a biolink:NamedEntity; rdfs:label "adult " . sub:_1 rdf:object ; rdf:predicate biolink:treats; rdf:subject ; a rdf:Statement . } sub:provenance { sub:assertion prov:generatedAtTime "2022-09-16T17:18:27+00:00"^^xsd:dateTime; prov:hadPrimarySource ; prov:wasAttributedTo ; prov:wasQuotedFrom "Fluoxetine is indicated for the acute and maintenance treatment of obsessions and compulsions in adult patients and in pediatric patients aged 7 to 17 years with Obsessive Compulsive Disorder (OCD)" . biolink: pav:version "2.3.0" . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCTQs+mANCSHWhIW/YPio468UdGNHsPvADpjfaW8um/v2L4AoDIANginfoU65VNbPT5D0ADt1y0uFNne3VEMr9Y+I2HFaz6IKj+LdYMJk6VUf5WJoImRHIX6BZQwcUc22CbTBFYxvqvp3UmmHrCrhLIZjDSyutExK3tOTRoMDjGowIDAQAB"; npx:hasSignature "jmq43jenvsyPvm7tT6pmj/Rk6QJjqCfJHSqUXN9vB1raOfi3H+1oH/XjSnlY0j+0IRI2XTty7p3De02UBArVXQV1EAfgbulB1Ejf3ieUbJokyGY4J2QUOKD070UxMlBWCUG4K5rUn9cJK45H2KVqBCZvCHbx0XCorDxN2uRLZsU="; npx:hasSignatureTarget this: . this: dct:created "2022-09-16T17:18:27+00:00"^^xsd:dateTime; pav:createdBy . }